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Abstract 
Two elvitegravir/cobicistat‐based therapies combined with emtricitabine/tenofovir disoproxil fumarate 
(EVG/c/FTC/TDF) or emtricitabine/tenofovir alafenamide fumarate (EVG/c/FTC/TAF) are currently 
available for HIV patients. This study evaluated the modifications in the lipid profile of patients who received 
these treatments in the last three years at our institution. A retrospective observational study in HIV‐infected 
patients who received EVG/c/FTC/TDF or EVG/c/FTC/TAF from January 2015 to January 2018 at a 
reference hospital in northwestern Spain was carried out. Epidemiological, clinical and immunovirological 
data were recorded. A statistical analysis was performed using SPSS software. A total of 384 EVG/c‐based 
therapies were initiated during the study period, 151 EVG/c/FTC/TDF and 233 EVG/c/FTC/TAF. A 
significantly negative influence in all the lipid profile parameters in experienced patients and total cholesterol 
(TC), and LDL‐C in naïve patients were observed after 48 weeks of treatment with EVG/c/FTC/TAF, while 
these parameters remained stable in the EVG/c/FTC/TDF group. During follow‐up, a greater proportion of 
patients had lipid levels above the normal range (63.1% TC, 56.2% LDL‐C) and new lipid‐modifying drugs 
were prescribed (11.9%) in the EVG/c/FTC/TAF group. The number of cardiovascular risk factors (OR 1.66 
[95% CI 1.01‐2.72]; P = 0.043) was recognised as an independent predictor of lipid‐lowering prescription for 
patients treated with both EVG/c/FTC/TDF and EVG/c/FTC/TAF. For patients treated with 
EVG/c/FTC/TAF, the mean total cholesterol to HDL ratio in the first 48 weeks of the study treatment was 
associated with a higher likelihood of lipid‐lowering prescription in multivariate analysis (OR 1.6 [95% CI 
1.12‐2.52]; P = 0.011). Significant changes in lipid profile have been observed in patients who have received 
EVG/c/FTC/TAF. It was necessary to prescribe almost twice the number of lipid‐lowering drugs to patients 
who received EVG/c/FTC/TAF (11.9%) vs EVG/c/FTC/TDF (4.7%). 
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1 INTRODUCTION 
Antiretroviral therapy (ART) has dramatically changed the prognosis of human 
immunodeficiency virus (HIV) infection, with a significant decrease in morbidities and mortalities 
related to AIDS. The availability of these drugs has been a key factor in prolonging the lives of 
those infected, whose life expectancy has increased from less than 2 years after AIDS illness in the 
past two decades in patients who receive optimum treatment in the present, approaching that of the 
general population.
1
 However, long‐term use of ART is not free from side effects, and has been 
related to worsening observed in glucose and lipid values and associated with the risk of 
developing atherosclerosis, coronary artery disease, and increased incidence of acute myocardial 
infarction.
2, 3
 In addition, the ageing population has brought about an increase in the incidence of 
comorbidities such as dyslipidaemia, hypertension and diabetes,
4
 while there is also a high rate of 
HIV‐smoking patients.5 Furthermore, HIV infection leads to a series of immunological changes (ie 
low CD4/CD8 ratio, low T cell proliferative potential, reduced T cell repertoire, increased IL‐6, 
increased T cell activation, reduced thymus function, reduced response to vaccines
6
) due to the 
baseline immune activation and persistent chronic inflammation caused by the virus, which can 
affect a diverse range of organs, thus leading to cardiovascular damage. Taking the above into 
account, it is clear that cardiovascular disease has now become one of the main causes of death in 
HIV patients.
2, 7
 Therefore, there is a great deal of concern about the cardiovascular health of HIV‐
infected individuals in the long term.  
 
National and international guidelines for the initial treatment of HIV‐infected patients8-10 
recommend the use of two nucleoside analogue reverse transcriptase inhibitors (NRTIs) plus a 
third active drug: an integrase strand transfer inhibitor (INSTI), a non‐nucleoside reverse 
transcriptase inhibitor (NNRTI), or a boosted protease inhibitor (PI).  
 
Among the NRTIs, tenofovir disoproxil fumarate (TDF) was approved by the American and 
European drugs regulatory authorities and was available for HIV treatment in 2002. Since its 
approval, this drug has been included in most recommended regimens and has been the most 
widely used NRTI for many years based on its established high efficacy and generally good 
tolerance, as demonstrated in clinical trials and real‐life studies.11-15 
 
Furthermore, using TDF‐containing NRTI regimens has improved lipid parameters, supporting 
a lipid‐lowering effect of TDF.16-18 Despite its favourable characteristics, TDF can have clinically 
significant renal toxic effects and lead to a greater decline in bone mineral density (BMD) relative 




Tenofovir alafenamide fumarate (TAF), a novel oral prodrug of tenofovir, was first approved 
in 2015 combined with emtricitabine, elvitegravir and cobicistat (EVG/c/FTC/TAF). TAF‐
containing regimens have less of an impact on measures of renal and bone safety compared with 
TDF‐containing regimens; this is believed to be due to the tenofovir alafenamide's reduced dose, 
which is enough to reach an optimal intracellular concentration of the active metabolite tenofovir‐
diphosphate, and consequently a significant reduction in plasma tenofovir concentrations.
19-21
 
Clinical guidelines hold that the use of the regimens containing TAF is preferred over those 




Variations in lipid levels in pivotal clinical trials of EVG/c/FTC/TAF were minimal, without 
clinical or statistical significance.
19, 21-25
 The present study evaluated modifications in the lipid 
profile in a large real‐world cohort of naïve and treatment‐experienced HIV patients who had 






Figure 1 Design of the study 
2 MATERIALS AND METHODS 
This was an observational study in adult HIV‐1‐infected patients who started antiretroviral 
therapy with EVG/c/FTC/TDF or EVG/c/FTC/TAF from 1 January 2015 to 31 January 2018 at a 
reference hospital in northwestern Spain. The selection of antiretroviral treatments for each patient 
was made based on clinical criteria and recommendations of the national clinical practice 
guidelines of each year, with no intervention. Only those patients who had signed the informed 
consent document and had at least one follow‐up visit were included. Those patients participating 
in clinical trials or who had been transferred from other centres (hospitals or penitentiaries) using 
the study drugs were excluded from the study. The study was conducted in accordance with the 
Basic & Clinical Pharmacology & Toxicology policy for experimental and clinical studies.
26
 
Epidemiological, clinical, immunovirological data and information regarding ART were 
retrospectively recorded. The time of follow‐up was defined as spanning from the day of 
EVG/c/FTC/TDF or EVG/c/FTC/TAF initiation until the day of discontinuation or the last clinical 
analysis in the follow‐up period. The basal lipid profile was compared with that at 48 weeks after 
receiving the study ART. The "Division of AIDS Table for Grading the Severity of Adult and 
Pediatric Adverse Events, Version 2.0"
27 
was considered for assessing the severity of laboratory 
abnormalities. Presence of the following cardiovascular risk factors was recorded: dyslipidaemia 
(total cholesterol ≥200 mg/dL, triglycerides ≥150 mg/dL, LDL‐C ≥130 mg/dL and/or treatment 
with lipid‐lowering agents registered in medical records), arterial hypertension (registered in 
medical records and/or antihypertensive treatment), diabetes mellitus (registered in medical 
records and/or treatment with oral glucose‐lowering agents or insulin) and smoking (current 
smoker, ex‐smoker and non‐smoker). In terms of adherence to antiretrovirals (according to 
hospital pharmacy records) or lipid‐lowering drugs (according to dispensations registered in 
electronic clinical history), ≥90% was considered optimal.  
  
A statistical analysis was performed using SPSS v.19. software. Group differences were 
compared using the Pearson χ
2
 or Fisher's exact test and Student's t‐test or the Mann–Whitney U 
test, respectively, for categorical and continuous variables. Repeated measurements were 
compared using a paired Student's t‐test or Wilcoxon's signed‐rank test. Univariate analyses were 
performed using all the covariates. Multivariate Cox regression analysis of the statistically 
significant univariate covariates as well as the clinically relevant covariates was performed to 
identify risk factors for lipid‐lowering drug prescriptions. P‐values of 0.05 or less were considered 
statistically significant.  
3 RESULTS 
3.1 Baseline characteristics of the study population 
A total of 384 EVG/c‐based therapies were initiated within the observation period at our 
institution: 151 patients started EVG/c/FTC/TDF and 233 EVG/c/FTC/TAF (Figure 1). Baseline 
characteristics were similar between groups. The majority of patients who received 
EVG/c/FTC/TDF and EVG/c/FTC/TAF were men, with a median age of 46 years, and they also 
received stable antiretroviral therapy (experienced). The most common acquisition risk factor for 
HIV infection was related to sexual activity for both groups. The immunovirological 
characteristics in naïve and experienced patients were similar between groups. There was a greater 
percentage of Caucasians in the EVG/c/FTC/TDF group and a higher rate of RNA‐HIV basal <50 
copies/mL in the EVG/c/FTC/TAF group (Table 1).  
  
Table 1. Baseline characteristics of the study population 
Variables EVG/c/FTC/TDF (n = 151)  EVG/c/FTC/TAF (n = 233)  P‐value  
 
Demographic‐epidemiological 
Male (%) 84.8 75.5 0.3566 
Age (years ± SD) 45.3 ± 9.1 46.5 ± 10.4 0.2455 
20‐40 years (%)  30.5 27.0 0.7224 
41‐60 years (%)  64.2 66.5 
>60 years (%)  5.3 6.4 
HIV risk factor 
MSM (%) 43.0 36.5 0.2326 
Heterosexual (%) 26.5 34.3 
IDU (%) 27.2 23.6 
Unknown (%) 3.3 5.6 
Ethnic origin 
Caucasian (%) 93.4 83.7 0.0051 
Latin (%) 6.6 13.3 
Black (%) 0.0 3.0 
Co‐infections 
Anti‐HCV positive (%) 23.2 23.2 0.8358 
HBsAg positive (%) 4.6 3.0 0.5792 
HIV status in naïve patients (%) 21.9 18.9 0.4777 
Mean CD4 (cells/µL ± SD) 435.6 ± 288.4 452.1 ± 379.3 0.8351 
Mean RNA‐HIV (log copies/mL ± SD) 4.8 ± 0.7 4.6 ± 0.9 0.4798 
HIV status in experienced patients 78.1 81.1  
Mean CD4 (cells/µL±SD) 607.2 ± 288.8 619.0 ± 319.0 0.7441 
RNA‐HIV basal (%VL<50 copies/mL) 76.3 85.7 0.0358 
Cardiovascular risk factors 
Smoking history 
Former (%)  12.6 13.3 0.8373 
Current (%)  46.4 41.2 0.3191 
Hypertension (%) 9.3 12.4 0.3352 
Diabetes (%) 4.6 5.6 0.6844 
Obesity (%) 4.6 3.9 0.9133 
Dyslipidaemia 23.2 27.5 0.3480 
Lipid‐lowering agents 
Statins (%)  7.3 12.4 0.1058 
Ezetimibe (%)  0.6 0.8 1.000 
Fibrates (%)  2.6 2.1 0.7426 
    
 
HDL‐C: HDL Cholesterol; IDU: intravenous drug use; LDL‐C: LDL Cholesterol; MSM: men who have sex with men; TC: 
Total Cholesterol; TG: Triglycerides; VL: viral load. 
In both groups, there was a high percentage of patients with at least one cardiovascular risk 
factor (71.5% in EVG/c/FTC/TDF vs 70.8% of the patients in EVG/c/FTC/TAF, P = 0.9322). The 
basal cardiovascular risk factors were similar in both the EVG/c/FTC/TDF and EVG/c/FTC/TAF 
treatment groups. No differences were seen in the ratio of basal lipid‐lowering agent prescriptions.  
  
3.2 Lipid profile variations in EVG/c/FTC/TDF group 
Experienced patients in the EVG/c/FTC/TDF treatment group did not show significant 
variation in their lipid profile when we compared the basal lipid values with those at 48 weeks 
after the start of the study treatment. Only in HIV treatment‐naïve patients, excluding those with 
lipid‐lowering treatment prescription (either prior [n = 1] or during follow‐up [n = 2] lipid‐
lowering prescription), statistically significant differences were observed in total cholesterol (TC; 
159.8 ± 31.9 vs 183.0 ± 28.6, P = 0.007) and HDL‐C (37.1 ± 13.8 vs 43.5 ± 14.0, P = 0.005). The 
rate of patients with values above the normal range before and 48 weeks after prescription of 
EVG/c/FTC/TDF was similar (Table 2). 
Table 2. Changes in lipid profiles after 48 weeks of study treatment excluding patients with lipid‐lowering treatment prescription 
 
EVG/c/FTC/TDF (n = 130)   EVG/c/FTC/TAF (n = 179)  
Basal WK48 P‐value   Basal WK48 P‐value  
 
Naïve patients 
Lipid levels (mean ± SD) 
TG mg/dL 115.5 ± 56.4 143.0 ± 106.6 0.795  125.8 ± 59.0 127.7 ± 69.7 0.758 
TC mg/dL 159.8 ± 31.9  183.0 ± 28.6  0.007   173.3 ± 44.8  209.6 ± 35.5  <0.001  
LDL‐C mg/dL 100.5 ± 22.0 112.4 ± 21.1 0.074  109.7 ± 40.5  132.1 ± 31.3  0.027  
HDL‐C mg/dL 37.1 ± 13.8  43.5 ± 14.0  0.005   43.0 ± 8.2  53.3 ± 12.6  <0.001  
TC:HDL‐C ratio 4.6 ± 1.1 4.4 ± 1.0 0.570  4.1 ± 0.9 4.1 ± 1.1 0.088 
LDL‐C/HDL‐C ratio 2.9 ± 0.8 2.7 ± 0.7 0.691  2.5 ± 0.9 2.6 ± 0.9 0.227 
Lipid levels out range (%) 
TG (≥150 mg/dL) 28.0 28.6 0.7750  32.4 23.5 0.5693 
TC (≥200 mg/dL) 12.0 19.0 0.8020  29.7  61.8  0.0135  
LDL‐C (≥130 mg/dL) 8.7 9.5 0.6676  28.1  57.6  0.0318  
TC:HDL‐C ratio (≥4.5 for men; ≥4.0 for women) 52.2 47.6 1.000  46.9 36.4 0.5432 
LDL‐C:HDL‐C ratio (≥3.0 for men; ≥2.5 for women) 43.5 38.1 0.9555  34.4 42.4 0.6804 
Experienced patients 
Lipid levels (mean ± SD) 
TG mg/dL 114.8 ± 58.0 121.6 ± 67.9 0.864  120 ± 64.2  148.9 ± 123.5  <0.001  
TC mg/dL 176.6 ± 36.1 177.5 ± 36.6 0.110  179.9 ± 35.8  208.9 ± 38.0  <0.001  
LDL‐C mg/dL 108.3 ± 29.6 109.2 ± 32.1 0.400  109.6 ± 30.9  130.5 ± 30.7  <0.001  
HDL‐C mg/dL 45.3 ± 16.9 45.7 ± 14.1 0.073  48.0 ± 19.7  51.3 ± 13.7  <0.001  
TC:HDL‐C ratio 4.1 ± 0.9 4.1 ± 1.1 0.980  4.0 ± 1.0  4.2 ± 1.0  0.001  
LDL‐C/HDL‐C ratio 2.5 ± 0.7 2.5 ± 0.9 0.841  2.4 ± 0.8  2.6 ± 0.7  0.002  
Lipid levels out range (%) 
TG (≥150 mg/dL) 14.6 23.9 0.2082  23.9 28.9 0.4476 
TC (≥200 mg/dL) 24.7 25.4 0.9252  25.9  63.2  <0.001  
LDL‐C (≥130 mg/dL) 23.8 24.3 0.9085  26.2  56.0  <0.001  
TC:HDL‐C ratio (≥4.5 for men; ≥4.0 for women) 37.5 34.3 0.8114  31.5 39.6 0.2393 
LDL‐C:HDL‐C ratio (≥3.0 for men; ≥2.5 for women) 32.5 32.9 0.8982  30.8 32.1 0.9342 
        
 
Statistically significant differences are shown in bold.  
HDL‐C: HDL Cholesterol; LDL‐C: LDL Cholesterol; TC: Total Cholesterol; TG: Triglycerides; WK48: Week 48  
 
 
In those patients with a lipid‐lowering prescription (n = 21, 13.9%), only 10 patients (47.6%) 
showed an adherence of ≥90% to lipid‐modifying agents. TC levels were significantly different 
among patients with an optimal and suboptimal adherence to lipid‐lowering drugs after 48 weeks 
of EVG/c/FTC/TDF (194.9 ± 26.3 vs 252.4 ± 47.1, P = 0.008; Table 3). In patients with an 
optimal lipid‐lowering drug adherence, significant differences were still found between basal TC 
and 48 weeks after beginning of EVG/c/FTC/TDF (218.3 ± 18.6 vs 194.9 ± 26.3, P = 0.043; Table 
4). 
Table 3. Lipid profiles after 48 weeks of study treatment in patients with and without optimal adherence to lipid‐lowering 
treatment 
Naïve & experienced 
patients 
EVG/c/FTC/TDF (n = 21)   EVG/c/FTC/TAF (n = 54)  
≥90% Adherence 
(n = 10)  
<90% Adherence 





(n = 34)  
<90% Adherence 




Lipid levels (mean ± SD) 
TG mg/dL 127.7 ± 34.6 173.4 ± 111.9 0.515  159.0 ± 71.8 134.5 ± 55.7 0.163 
TC mg/dL 194.8 ± 26.3  252.3 ± 47.0  0.008   220.5 ± 47.6 242.5 ± 78.6 0.537 
LDL‐C mg/dL 126.0 ± 26.9 156.1 ± 22.1 0.065  139.6 ± 43.2 150.8 ± 40.4 0.460 
HDL‐C mg/dL 42.6 ± 6.5 44.4 ± 5.9 0.587  49.6 ± 14.9 47.4 ± 12.7 0.860 
TC:HDL‐C 
ratio 
4.6 ± 1.0 5.4 ± 0.9 0.104  4.7 ± 1.2 5.2 ± 2.0 0.699 
LDL‐C/HDL‐C 
ratio 
3.0 ± 0.9 3.5 ± 0.2 0.233  3.0 ± 1.0 3.5 ± 1.4 0.367 
        
 
≥90% dispensations registered in electronic clinical history of the patient was considered optimal adherence. Statistically 
significant differences are shown in bold.  
HDL‐C: HDL Cholesterol; LDL‐C: LDL Cholesterol; TC: Total Cholesterol; TG: Triglycerides  
Table 4. Changes in lipid profiles after 48 weeks of study treatment in patients with optimal adherence to lipid‐lowering 
treatment 
Naïve & experienced patients 
EVG/c/FTC/TDF (n = 10)   EVG/c/FTC/TAF (n = 34)  
Basal WK48 P‐value   Basal WK48 P‐value  
 
Lipid levels (mean ± SD) 
TG mg/dL 146.3 ± 45.4 127.7 ± 34.6 0.310  133.6 ± 54.4  159.0 ± 71.8  0.005  
TC mg/dL 218.2 ± 18.6  194.8 ± 26.3  0.043   199.6 ± 34.9  220.5 ± 47.6  0.006  
LDL‐C mg/dL 146.0 ± 11.0 126.0 ± 26.9 0.063  125.5 ± 34.2  139.6 ± 43.2  0.032  
HDL‐C mg/dL 42.4 ± 5.5 42.6 ± 6.5 0.116  47.3 ± 16.8 49.6 ± 14.9 0.106 
TC:HDL‐C ratio 5.1 ± 0.6 4.6 ± 1.0 0.063  4.5 ± 1.2 4.7 ± 1.2 0.318 
LDL‐C/HDL‐C ratio 3.4 ± 0.5 3.0 ± 0.9 0.128  2.8 ± 0.9 3.0 ± 1.0 0.531 
        
 
≥90% dispensations registered in electronic clinical history of the patient was considered optimal adherence. Statistically 
significant differences are shown in bold.  
HDL‐C: HDL Cholesterol; LDL‐C: LDL Cholesterol; TC: Total Cholesterol; TG: Triglycerides; WK48: Week 48  
  
3.3 Lipid profile variations in the EVG/c/FTC/TAF group 
Patients in the EVG/c/FTC/TAF treatment group showed significant variations in their lipid 
profile when we compared basal lipid values with those at 48 weeks after the start of the study 
treatment. When patients in lipid‐lowering treatment were excluded (either those with prior 
[n = 32] or during follow‐up [n = 22] lipid‐lowering prescription) and basal lipid levels were 
compared with those at 48 weeks, statistically significant differences were observed in all the lipid 
profile evaluation parameters among experienced patients and in TC, LDL‐C and HDL‐C among 
naïve patients. A higher percentage of both naïve and experienced patients had lipid levels above 
the normal range after 48 weeks of EVG/c/FTC/TAF (Table 2).  
 
Experienced patients with a previous ART based on TDF (63.1%) had a worse lipid profile 
after 48 weeks of EVG/c/FTC/TAF: triglycerides (TG; 122.6 ± 67.3 vs 152.9 ± 130.3, 
P = 0.0410), TC (179.8 ± 33.7 vs 209.1 ± 36.1, P < 0.001), LDL‐C (109.3 ± 30.5 vs 129.8 ± 29.8, 
P < 0.001), HDL‐C (47.4 ± 20.6 vs 50.7 ± 13.2, P = 0.1751), TC:HDL‐C ratio (4.0 ± 0.8 vs 
4.2 ± 0.9, P = 0.007) and LDL‐C/HDL‐C ratio (2.5 ± 0.6 vs 2.6 ± 0.6, P = 0.044). However, in 
experienced patients with a previous ART based on other than TDF, only statistical differences 
were found in TC (181.1 ± 41.9 vs 192.9 ± 41.7, P = 0.047), and LDL‐C (106.4 ± 34.6 vs 
116.3 ± 35.9, P = 0.031).  
 
The analysis performed in experienced patients with regard to the third active drug received 
before the start of EVG/c/FTC/TAF showed statistical differences in: TC (185.9 ± 43.7 vs 
217.0 ± 37.1, P = 0.0038), and LDL‐C (112.0 ± 35.9 vs 134.7 ± 28.3, P = 0.0082) among previous 
PI users (27.0%); in TC (183.8 ± 33.4 vs 208.2 ± 39.1, P = 0.0054), LDL‐C (114.4 ± 26.6 vs 
131.0 ± 33.6, P = 0.0231), TC:HDL‐C ratio (4.0 ± 0.8 vs 4.2 ± 0.9, P = 0.003), and LDL‐C/HDL‐
C ratio (2.4 ± 0.6 vs 2.6 ± 0.7, P = 0.005) among previous NNRTI users (28.6%); and in TG 
(120.7 ± 58.4 vs 174.0 ± 167.4, P = 0.0329), TC (173.7 ± 31.4 vs 205.0 ± 37.8, P < 0.001), and 
LDL‐C (104.9 ± 30.0 vs 127.6 ± 30.2, P = 0.0002) among previous INSTI (44.4%) users.  
 
About 62.9% of those patients with a lipid‐lowering prescription showed an adherence of 
≥90% to these drugs. No differences were observed in the lipid profile between adherent and non‐
adherent patients (Table 3). In patients with an optimal lipid‐lowering adherence, significant 
differences were still found in TC, LDL‐C and TG between basal and 48 weeks after 
EVG/c/FTC/TAF prescription (199.6 ± 34.9 vs 220.5 ± 47.6, P = 0.006; 125.5 ± 34.3 vs 
139.6 ± 43.2, P = 0.032; 133.7 ± 54.4 vs 159.1 ± 71.9, P = 0.005, respectively; Table 4).  
3.4 Lipid profile variations between groups 
Similar baseline lipid levels were seen in the two study groups in both naïve and experienced 
patients, both when considering the entire study population and when excluding those patients 
with lipid‐lowering drug prescription (Table 5). The lipid levels of EVG/c/FTC/TDF and 
EVG/c/FTC/TAF that showed differences at week 48 included TC (183.0 ± 28.6 vs 209.6 ± 35.5, 
P = 0.0055), LDL‐C (112.4 ± 21.1 vs 132.1 ± 31.3, P = 0.0145), and HDL‐C (43.5 ± 14.0 vs 
53.3 ± 12.6, P = 0.0105) among naïve; and TC (177.5 ± 36.6 vs 208.9 ± 38.0, P < 0.0001), LDL‐C 
(109.2 ± 32.1 vs 130.5 ± 30.7, P < 0.001), and HDL‐C (45.7 ± 14.1 vs 51.3 ± 13.7, P = 0.0083) 
among experienced patients, excluding those patients with lipid‐lowering drug prescriptions 
(Table 5).  
  
Table 5. Basal and After 48 weeks comparison between EVG/c/FTC/TDF versus EVG/c/FTC/TAF, excluding patients 
with lipid‐lowering treatment prescription 
Lipid levels 
(mean ± SD) 
BASAL  WK48 
EVG/c/FTC/TDF 
(n = 130) 
EVG/c/FTC/TAF 





(n = 130) 
EVG/c/FTC/TAF 





TG mg/dL 115.5 ± 56.4 125.8 ± 59.0 0.4952  143.0 ± 106.6 127.7 ± 69.7 0.5655 
TC mg/dL 159.8 ± 31.9 173.3 ± 44.8 0.1992  183.0 ± 28.6  209.6 ± 35.5  0.0055  
LDL‐C mg/dL 100.5 ± 22.0 109.7 ± 40.5 0.2821  112.4 ± 21.1  132.1 ± 31.3  0.0145  
HDL‐C mg/dL 37.1 ± 13.8 43.0 ± 8.2 0.0750  43.5 ± 14.0  53.3 ± 12.6  0.0105  
TC:HDL‐C ratio 4.6 ± 1.1 4.1 ± 0.9 0.1008  4.4 ± 1.0 4.1 ± 1.1 0.3256 
LDL‐C/HDL‐C 
ratio 
2.9 ± 0.8 2.5 ± 0.9 0.1586  2.7 ± 0.7 2.6 ± 0.9 0.6745 
Experienced patients 
TG mg/dL 114.8 ± 58.0 120 ± 64.2 0.4883  121.6 ± 67.9 148.9 ± 123.5 0.0546 
TC mg/dL 176.6 ± 36.1 179.9 ± 35.8 0.5195  177.5 ± 36.6  208.9 ± 38.0  <0.001  
LDL‐C mg/dL 108.3 ± 29.6 109.6 ± 30.9 0.7664  109.2 ± 32.1  130.5 ± 30.7  <0.001  
HDL‐C mg/dL 45.3 ± 16.9 48.0 ± 19.7 0.3210  45.7 ± 14.1  51.3 ± 13.7  0.0083  
TC:HDL‐C ratio 4.1 ± 0.9 4.0 ± 1.0 0.5334  4.1 ± 1.1 4.2 ± 1.0 0.4492 
LDL‐C/HDL‐C 
ratio 
2.5 ± 0.7 2.4 ± 0.8 0.5318  2.5 ± 0.9 2.6 ± 0.7 0.4387 
        
 
Statistically significant differences are shown in bold.  
HDL‐C: HDL Cholesterol; LDL‐C: LDL Cholesterol; TC: Total Cholesterol; TG: Triglycerides; WK48: Week 48  
Prescription of lipid‐lowering drugs in naïve patients was similar for both the EVG/c/FTC/TAF 
(7.1%) and EVG/c/FTC/TDF (6.2%) groups (P = 1.000). Experienced patients in treatment with 
EVG/c/FTC/TAF were more likely to receive a new lipid‐lowering prescription compared to those 
receiving EVG/c/FTC/TDF (11.9% vs 4.7%, P = 0.0468).  
 
During follow‐up, 14 patients in the EVG/c/FTC/TDF group (9.2%) and 10 patients in the 
EVG/c/FTC/TAF group (4.2%) discontinued treatment due to adverse events (AE; P = 0.0489): 
gastrointestinal discomfort (3.3% vs 0.8%, P = 0.1171), alterations of renal function (2.6% vs 
0.0%, P = 0.0233), events related to neuropsychiatric disturbances (2.0% vs 0.8%, P = 0.3857), 
headache and arthralgia (1.3% vs 0.0%, P = 0.1540), and hyperlipidaemia (0.0% vs 2.6%, 
P = 0.0854; Table 6). Patients who took longer to discontinue treatment due to adverse effects 
were those in whom hyperlipidaemia was manifested (429.6 ± 109.5 days), followed by patients 
with alterations of renal function (174.5 ± 114.7 days), gastrointestinal discomfort 
(141.0 ± 124.7 days), and neuropsychiatric disturbances (67.6 ± 66.0 days).  
  
Table 6. Adverse events leading to study drug discontinuation 
 
EVG/c/FTC/TDF (n = 151)  EVG/c/FTC/TAF (n = 233)  P‐value  
    
Any adverse event 14 (9.2%) 10 (4.2%) 0.0489 
Gastrointestinal discomfort 5 (3.3%) 2 (0.8%) 0.1171 
Alterations of renal function 4 (2.6%) 0 (0.0%) 0.0233 
Neuropsychiatric disturbances 3 (2.0%) 2 (0.8%) 0.3857 
Headache and arthralgia 2 (1.3%) 0 (0.0%) 0.1540 
Hyperlipidaemia 0 (0.0%) 6 (2.6%) 0.0854 
    
 
In the follow‐up period, no differences were found in the number of patients who suffered an 
acute coronary syndrome (0.6% in the EVG/c/FTC/TDF group vs 1.2% in the EVG/c/FTC/TAF 
group, P = 0.999). Two patients in both groups died during follow‐up (P = 0.6246); these deaths 
were not related to antiretroviral treatment or cardiovascular events.  
 
A univariate analysis of risk factors for lipid‐lowering prescription was performed considering 
age, gender, ethnic origin, routes of HIV transmission, HBV and HCV coinfection, treatment 
experience (naïve vs experienced), previous ART (TDF and PI, NNRTI or INSTI), current ART 
(EVG/c/FTC/TDF or EVG/c/FTC/TAF), number of cardiovascular risk factors and mean lipid 
profile in the first 48 weeks of the study treatment. 
 
Age (odds ratio 1.04 [95% confidence interval (CI) 1.00‐1.08]; P = 0.033), especially in those 
patients between 41 and 60 years old (5.71 [95% CI 1.32‐24.63]; P = 0.019) and the number of 
cardiovascular risk factors (1.81 [95% CI 1.13‐2.90]; P = 0.0013) were associated with an 
increased risk of lipid‐lowering prescription in patients treated with both EVG/c/FTC/TDF and 
EVG/c/FTC/TAF. In the multivariate analysis, only the number of cardiovascular risk factors 
(1.66 [95% CI 1.01‐2.72]; P = 0.043) was recognised as an independent predictor of lipid‐lowering 
prescription after adjusting for age, gender and current ART for patients treated with both 
EVG/c/FTC/TDF and EVG/c/FTC/TAF.  
 
For patients in treatment with EVG/c/FTC/TAF, only the mean TC:HDL‐C ratio in the first 
48 weeks of the study treatment was associated with a more likely lipid‐lowering prescription; 
indeed, this was shown by univariate analysis (1.9 [95% 1.3‐2.9]; P = 0.001) as well as 
multivariate analysis (1.6 [95% CI 1.12‐2.52]; P = 0.011) after adjusting for age and number of 
cardiovascular risk factors.  
4 DISCUSSION 
This study provides the first experience in real clinical practice regarding lipid profile 
alterations in patients being treated with EVG/c/FTC/TAF. Our findings show that this fixed 
combination had a negative influence on the lipid profile after 48 weeks’ treatment, both in naïve 
and in experienced patients. This worsening of the lipid parameters has not been observed during 
the treatment with the EVG / c / FTC combination with tenofovir disoproxil fumarate. These 
unexpected results in the EVG/c/FTC/TAF group show how the lipid profile of patients varies, 
providing more data than has previously been published by clinical trials. 
  
Over the last three years, several studies have compared TDF with TAF regimens in terms of 
efficacy and safety, some of them in combination with EVG/c/FTC.
19, 21-25
 In those studies of both 
treatment‐naïve and suppressed patients switching to regimens based on TAF, the drug seems to 
have a minimum effect on the lipid profile. In the two blinded and controlled studies in treatment‐
naïve patients,
19, 22
 greater lipid concentrations (TG, TC, HDL‐C and LDL‐C) were seen in the 
EVG/c/FTC/TAF group compared to the EVG/c/FTC/TDF group (P < 0.001) at week 48, and the 
authors relate this to significant reductions in plasma tenofovir concentrations with TAF. These 
results are similar to what we observed in our naïve patients when we compared the two treatment 
groups. As in clinical trials, we also found no differences in the TC:HDL‐C ratio (associated with 
cardiovascular disease risk) between groups or in cardiovascular or cerebrovascular events, nor in 
the proportion of participants initiating lipid‐modifying agents in naïve patients, although the 
proportion in our study (7.1%) was higher than in clinical trials (3.6%) for patients given 
EVG/c/FTC/TAF.  
 
There exist other clinical trials in which TAF/FTC has also been evaluated against TDF/FTC in 
naïve patients combined with other than EVG/c.
25, 28
 Mills et al saw greater increases in the fasting 
lipid parameters (TG, TC, LDL‐C and HDL‐C) in the TAF group compared with the TDF group at 
week 48, while in the Sax et al study, changes in fasting lipids were similar between regimens. 
There were no differences in the TC:HDL‐C ratio, treatment‐related cardiovascular events, or in 
the number of participants who were started on lipid‐lowering medications during the study; with 
this said, however, in the Mills et al study, a similar percentage of these drugs was prescribed in 
the TAF group compared to that of our study (6.8%).  
 
Among treatment‐experienced patients, both in clinical trials with EVG/c/FTC/TAF24 and 
FTC/TAF combined with another third agent,
21, 23
 lipid values increased from baseline in the TAF 
group while remaining stable in the TDF group at weeks 48 and 96; however, the authors 
concluded that median changes in lipid values were minimal from a clinical standpoint and the 
median changes in TC:HDL‐C ratio were similar21, 23 or minimal.24 Our data are in contrast with 
those reported in trials and highlight that experienced patients encountered an important worsening 
of their lipid profile and a significant change in TC:HDL‐C and LDL‐C:HDL‐C ratios. 
Furthermore, a high percentage of patients in the EVG/c/FTC/TAF group exceeded values above 
the normal range of cholesterol (40%) and LDL‐C (30%) after 48 weeks of treatment. It is for this 
reason that we also saw in our study that these patients had a higher percentage of lipid‐lowering 
prescription than the EVG/c/FTC/TDF group (11.9% vs 4.7%, P = 0.0468), which also contrasts 
with what was reported in clinical trials (4% in both groups in one of the studies,
21
 and FTC/TAF 
7.2% vs FTC/TDF 6.4%, P = 0.76 in the other clinical trial
23
). Reported frequency of lipid‐related 
or cardiovascular adverse events was similar between the two groups, similar to what was 
observed in our study.  
 
In all these clinical trials, the authors conclude that the lower concentrations of tenofovir in 
plasma from TAF when compared with TDF, and the lipid‐lowering effect of tenofovir, may 
explain the statistically significant increases in lipid profile in the TAF group compared with the 
TDF group. Changes in lipid levels were reported to be of minimal clinical relevance and were not 
deemed to be an adverse effect of TAF but rather an effect of an absence of high plasma tenofovir 
concentrations. Treatment with TDF has consistently been associated with lower lipids compared 
with other regimens in treatment‐naïve or virologically suppressed individuals.16, 17, 24 
 
Switching TDF to TAF leads to an increase in lipids and, conversely, lipid parameters improve 
when HIV‐positive individuals switch to TDF; indeed, this was seen in the six patients who 
discontinued EVG/c/FTC/TAF due to hyperlipidaemia and returned to their previous treatment, 
which was based on TDF. Adding TDF to a fully suppressive regimen decreases TC by 
36.5 mg/dL and LDL‐C by 20 mg/dL;17 very similar increases values were observed in our study 
when experienced patients changed to EVG/c/FTC/TAF.  
  
All clinical trials suggested that although overall safety was similar, EVG/C/FTC/TAF had a 
favourable long‐term renal and bone safety profile. For these reasons, recent HIV treatment 
guidelines have either replaced TDF with TAF or included both as part of recommended initial 
regimens, and advised TAF or abacavir in patients who cannot receive TDF due to renal 
dysfunction or osteoporosis. The recommendations in clinical guidelines aim to minimise the risk 
factors and the development of renal and bone events in these patients. However, it is important to 
keep in mind that although the clinical trials concluded that changes from baseline in fasting lipid 
concentrations were generally similar between groups and not deemed clinically relevant, in real‐
life experience we observed an increase in lipid levels, a significant increase in TC:HDL‐C 
(associated with cardiovascular disease risk) and an increase in lipid‐lowering prescription, which 
could give rise to an increase in cardiovascular risk. These data should also be evaluated when 
recommendations are made by clinical practice guidelines, especially knowing that the HIV 
population is more susceptible to cardiovascular risk than the general population, and that the use 
of TDF has been linked to reduced lipid levels in HIV patients when compared with other 
nucleoside reverse transcriptase inhibitors. 
 
Among a large cohort of HIV‐infected patients actively using antiretrovirals between 2002 and 
2011,
14
 TDF use was strongly associated with lower risk of heart failure incidents. Compared with 
never users of TDF, current users of TDF and patients whose initial regimen included TDF had 
reductions in heart failure risk ranging from 30% to 50%. One of the mechanisms suggested by the 
authors for a potential protective effect could be TDF's lipid‐lowering effects, which could create a 
potentially beneficial reduction in atherosclerosis and subsequent coronary artery disease.  
 
Cardiovascular disease is already an important contributor to overall morbidity and has become 
one of the leading causes of death among HIV‐infected patients in countries with established 
antiretroviral treatment programmes. Compared with the general population, people living with 
HIV have a 1.5‐ to 2‐times increased risk of cardiovascular disease.7, 14, 29-31 Fontenla et al 
estimated that over three quarters had a minimum of one cardiovascular risk factor2 with 
dyslipidaemia and smoking being the most frequent ones, similar to what we observed in our study 
population. Smoking has been found to be associated with a greater risk of myocardial infarction 
in the HIV‐infected population than in the general population,31 and nearly 50% of our study 
population were smokers. Dyslipidaemia is considered a major risk factor for cardiovascular 
disease. The prevalence of dyslipidaemia in large HIV cohort studies has ranged from 31% to 81% 
based on various definitions used for dyslipidaemia.
31
 In our study, more than 25% of the patients 
in both groups had baseline dyslipidaemia, which contrasts significantly with the values at 
48 weeks in the EVG/c/FTC/TAF group (63%).  
 
A prospective cohort (APROCO/COPILOTE Cohort Study
32
) with a median follow‐up of 
7.3 years reported a higher incidence of non‐AIDS events than that of antiretroviral treatment‐
related and AIDS‐defining events (10.5, 3.6 and 2.6 per 100 patient years, respectively). Bacterial 
infections were the most frequent non‐AIDS events (23.4%), followed by non‐AIDS‐defining 
malignancies and cardiovascular events (both 9.5%). Based on data from the 
APROCO/COPILOTE Cohort Study Factors, the rate of patients with cardiovascular events was 
higher than that of patients experiencing ART clinical events.  
 
As expected, HIV patients in our study with more risk factors and a higher age were more 
likely to receive a new lipid‐lowering prescription, as has been seen in other studies.31 
Surprisingly, in the EVG/c/FTC/TAF group, it seemed that neither age nor number of 
cardiovascular risk factors influenced the prescription of lipid‐lowering drugs, although the 
TC:HDL‐C ratio did; indeed, this implies that even young patients or those with few 
cardiovascular disease risk factors will receive these lipid‐lowering drugs if there is an elevation of 
the TC:HDL‐C ratio values.  
  
Lipid‐lowering drugs, and statins in particular, are not free from adverse events. The most 
common event is myotoxicity, which is present in approximately 10%‐25% of patients undergoing 
treatment, but commonly associated with muscle weakness, elevated liver enzymes and an 
accelerated diabetes mellitus process.
33
 Therefore, statins should be carefully prescribed; this is 
also important because they may present drug‐drug interaction with ART. It must also be taken 
into account that although statins are prescribed, there are barriers to the successful controlling of 
dyslipidaemia, which could include non‐adherence, perceived drug side effects, polypharmacy, 
costs of statins, suboptimal physician provider/patient relationships, and overestimation of the 
effect of diet control.
4, 31, 34
 Around 40% of the patients in our study were non‐adherent to lipid‐
lowering drugs; therefore, there could be a problem derived from not achieving therapeutic 
success, which is necessary if the patient has elevated lipid levels.  
 
Several factors may probably explain the conflicting results observed between trials and our 
data. Those who might partially explain these findings is the older population in our study 
(46 years) compared to that in the clinical trials
19, 25, 28
 (31‐35 years), and the observational 
research design. Although there were differences between the groups in two baseline variables, 
one of them, ethnic origin, was considered in the univariate analysis of risk factors for lipid‐
lowering prescription, with the results revealing that it had no influence. The higher rate of RNA‐
HIV basal <50 copies/mL observed in the EVG/c/FTC/TAF group might reflect a higher 
adherence to ART, which could have an impact on the lipid values at WK48. However, since no 
differences at baseline in the lipid profile were observed between groups, the impact of these 
baseline differences in the lipid values at WK48, if they exist, should be very low. The main 
limitation of the study was missing information regarding management of dyslipidaemia using 
lifestyle modifications such as dietary changes and exercise; indeed, this may explain why some 
patients were not prescribed lipid‐lowering drugs. Other limitations included the small sample 
size, the single‐centre nature of the study, and the retrospective observational design, which might 
have introduced uncontrolled bias.  
 
In summary, in this study, lipid levels increased from baseline in the EVG/C/FTC/TAF group 
while remaining stable in the EVG/c/FTC/TDF group after 48 weeks of treatment, both in naïve 
and experienced patients. As a result, a higher rate of patients had lipid levels out of range and a 
new prescription of lipid‐modifying drug was needed in the EVG/c/FTC/TAF group. Age and 
higher cardiovascular risk factors were predictors of receiving a new lipid‐lowering drug 
prescription for the whole study population. However, for patients in the EVG/c/FTC/TAF group, 
mean TC:HDL‐C ratio in the first 48 weeks of treatment was the predictor of initiation of a lipid‐
lowering drug regardless of the age and cardiovascular risk factors of the patient. 
 
Compared with EVG/c/FTC/TDF, EVG/c/FTC/TAF seemed to have the advantages of 
improving renal and bone parameters based on clinical trials. The clinical significance of this 
observed change in lipid levels is unclear, but it is necessary to take it into account, because the 
ageing of HIV‐infected patients on ART is associated with a high prevalence of comorbidities and 
risk factors that necessitate careful monitoring, and adequate control of chronic diseases, as well as 
the risk factors of these diseases. This observation requires robust exploration in appropriately 
designed studies and powerful cohorts with more patients. 
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